FDA Grants Accelerated Approval to Inovio’s VOCERYQ
The FDA approved the immunotherapy to reduce surgery frequency in adults with recurrent respiratory papillomatosis.
The FDA approved the immunotherapy to reduce surgery frequency in adults with recurrent respiratory papillomatosis.